The drug will likely gain approval to be covered by medical benefit schemes across numerous markets. The subsidised price is unlikely to approach the price received by PRR in most instances.
Additionally, the costs are subjective, and many could afford the treatment, even excluding the aid of medical benefit schemes.
The drug will likely gain approval to be covered by medical...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $417.6M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $235.7K | 795.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 83920 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 133347 | 14 |
View Market Depth
| Last trade - 11.50am 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |